Halozyme Therapeutics (NASDAQ: HALO) revenue
Halozyme Therapeutics reported revenue of $1,397m for fiscal 2025, 37.6% more than in fiscal 2024 ($1,015m). Since fiscal 2016 its revenue has grown by 852.1%, an average growth of 28.5% a year.
Halozyme Therapeutics has grown its revenue for 7 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2018, −52.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,397m | +37.6% | $469.0m | 33.6% |
| 2024 | $1,015m | +22.4% | $551.5m | 54.3% |
| 2023 | $829.3m | +25.6% | $337.6m | 40.7% |
| 2022 | $660.1m | +48.9% | $267.5m | 40.5% |
| 2021 | $443.3m | +65.7% | $275.9m | 62.2% |
| 2020 | $267.6m | +36.5% | $144.3m | 53.9% |
| 2019 | $196.0m | +29.1% | −$67.6m | −34.5% |
| 2018 | $151.9m | −52.0% | −$69.3m | −45.7% |
| 2017 | $316.6m | +115.8% | $81.0m | 25.6% |
| 2016 | $146.7m | — | −$83.2m | −56.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Halozyme Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Halozyme Therapeutics ranks 131st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Halozyme Therapeutics, 37.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 129th | Addus HomeCare | $1,423m | 23.2% |
| 130th | Penumbra | $1,404m | 17.5% |
| 131st | Halozyme Therapeutics | $1,397m | 37.6% |
| 132nd | LivaNova | $1,388m | 10.7% |
| 133rd | Conmed | $1,375m | 5.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Halozyme Therapeutics
- How much revenue did Halozyme Therapeutics make in fiscal 2025?
- Halozyme Therapeutics reported revenue of $1,397m for fiscal 2025, compared with $1,015m in fiscal 2024.
- How much has the revenue of Halozyme Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $146.7m to $1,397m: 852.1% more, an average growth of 28.5% a year.
- What was the best year for revenue at Halozyme Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $1,397m.
- Where does Halozyme Therapeutics rank in its sector by revenue?
- It ranks 131st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Halozyme Therapeutics come from?
- From the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Halozyme Therapeutics: the Halozyme Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.